Acura Pharmaceuticals Profile

USD 0.03  18.2%

Acquisition by Bruce Wesson of 22026 shares of Acura Pharmaceuticals subject to Rule 16b-3

Acura Pharmaceuticals insider trading alert for grant of restricted stock units by Bruce Wesson, the corporate stakeholder, on August 23, 2018. This event was filed by Acura Pharmaceuticals Inc with SEC on 2016-01-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Acura Pharmaceuticals Summary

Acura Pharmaceuticals [ACUR] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Acura Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Nano-Cap' category with current market capitalization of 5.76 M. Acura Pharmaceuticals conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 21.03 M outstanding shares of which 89.85 K shares are presently shorted by private and institutional investors with about 0.73 trading days to cover. ACURA PHARMACEUTI currently holds about 774 K in cash with (6.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
Check Acura Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Acura Pharmaceuticals Target Price Odds Analysis

Odds Below 0.1546HorizonTargetOdds Above 0.1546
36.09%30 days 0.15 63.83%
Based on normal probability distribution, the odds of Acura Pharmaceuticals to move above current price in 30 days from now is about 63.83% (This Acura Pharmaceuticals probability density function shows the probability of Acura Pharmaceuticals OTC Stock to fall within a particular range of prices over 30 days) .

Acura Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Acura Pharmaceuticals Key Fundamentals

Acura Pharmaceuticals Against Markets

Acura Pharmaceuticals Current Ratings

Acura Pharmaceuticals 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Acura Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. The company was founded in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and traded on BATS Exchange. It employs 14 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Acura Pharmaceuticals SEC Filings
Acura Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameAcura Pharmaceuticals
CEO and President and DirectorRobert JonesView All
Analyst Consensus
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA OTC Stock View All
RegionNorth America
Business Address616 N. North Court
ExchangeBATS Exchange
CIK Number0000786947
IndustryPharmaceutical Products
Phone847 705 7709
CurrencyUSD - US Dollar

Acura Pharmaceuticals Directors

Acura Pharmaceuticals Corporate Directors

George Ross Independent Director
Bruce Wesson Independent Director
Immanuel Thangaraj Independent Director
Check also Trending Equities. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.